Fortive Schedules Q4 2025 Earnings Call for February 4, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Source: Newsfilter
- Earnings Call Announcement: Fortive has scheduled its Q4 2025 earnings conference call for February 4, 2026, at 12:00 p.m. ET, lasting approximately one hour, aimed at updating investors on the company's financial performance and strategic direction.
- Webcast Availability: The call will be webcast on the 'Investors' section of Fortive's website, ensuring global investors can access real-time financial information, thereby enhancing transparency and investor relations.
- Dial-in Instructions: Investors can join the call by dialing 877-407-3110 within the U.S. or +1 215-268-9915 internationally, with a recommendation to call in a few minutes early, reflecting the company's commitment to investor engagement.
- Post-call Recording: A digital recording of the call will be available on Fortive's website after the conclusion of the meeting, allowing investors who could not attend live to review the content, further improving information accessibility and interaction with investors.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on FTV
Wall Street analysts forecast FTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FTV is 56.73 USD with a low forecast of 51.00 USD and a high forecast of 66.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
2 Buy
8 Hold
1 Sell
Hold
Current: 52.800
Low
51.00
Averages
56.73
High
66.00
Current: 52.800
Low
51.00
Averages
56.73
High
66.00
About FTV
Fortive Corporation is a technology solutions company. The Company's businesses design, develop, manufacture, and market products, software, and services, building on brand names, technologies, and market positions. The Company's segments include Intelligent Operating Solutions (IOS) and Advanced Healthcare Solutions (AHS). The Company's IOS segment provides advanced instrumentation, software and services to various customers enabling their mission-critical workflows. These offerings include electrical test and measurement, facility and asset lifecycle software applications, connected worker safety and compliance solutions across a range of vertical end markets. Its AHS segment supplies critical workflow solutions enabling healthcare providers to deliver patient care more efficiently. Its offerings include instrument sterilization solutions, instrument tracking, biomedical test tools, radiation detection and safety monitoring and end-to-end clinical productivity software and solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ASP International and FUJIFILM Healthcare Launch ULTRA GI™ Cycle, Securing CE Mark Approval
- CE Mark Approval: The ULTRA GI™ Cycle, launched by ASP in collaboration with FUJIFILM Healthcare, has received CE mark approval, representing a significant advancement in enhancing patient safety across healthcare facilities and addressing the complexities of traditional reprocessing methods.
- Technological Innovation: By integrating hydrogen peroxide gas plasma sterilization, the ULTRA GI™ Cycle boosts clinician confidence, allowing them to focus more on patient care and advancing the safety of duodenoscope reprocessing in Europe.
- Device Compatibility: ASP is prioritizing collaboration with medical device manufacturers to ensure new duodenoscope models are compatible with hydrogen peroxide, further expanding the technology platform and maximizing the value of existing customer investments.
- Enhanced Infection Control: The partnership between ASP and FUJIFILM Healthcare has resulted in a sterilization approach that exceeds current industry benchmarks, significantly elevating patient safety standards and aiding healthcare professionals in tackling the infection control challenges posed by duodenoscopes.
Continue Reading
Fortive Schedules Q4 2025 Earnings Call for February 4, 2026
- Earnings Call Announcement: Fortive has scheduled its Q4 2025 earnings conference call for February 4, 2026, at 12:00 p.m. ET, lasting approximately one hour, aimed at updating investors on the company's financial performance and strategic direction.
- Webcast Availability: The call will be webcast on the 'Investors' section of Fortive's website, ensuring global investors can access real-time financial information, thereby enhancing transparency and investor relations.
- Dial-in Instructions: Investors can join the call by dialing 877-407-3110 within the U.S. or +1 215-268-9915 internationally, with a recommendation to call in a few minutes early, reflecting the company's commitment to investor engagement.
- Post-call Recording: A digital recording of the call will be available on Fortive's website after the conclusion of the meeting, allowing investors who could not attend live to review the content, further improving information accessibility and interaction with investors.
Continue Reading